Convelo Therapeutics is developing a new class of medicines that unlock the regenerative capacity of the central nervous system. Convelo is pioneering approaches to regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases including multiple sclerosis, pediatric leukodystrophies, traumatic injury and age-related pathologies such as Alzheimer’s. Convelo has identified key biological targets and a pipeline of drug candidates to provide novel and meaningful solutions for patients and their families.

Biotechnology

Convelo Therapeutics

Derrick Rossi

Drew Adams

Paul Tesar

Samantha Stubblefield

Edmond Mok

Dan Factor

Brad Lang

Scientific Research Team

Leadership Team

Teams at Convelo Therapeutics

Scientific Research Team

Leadership Team